Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
Influenza, Herpes Zoster
About this trial
This is an interventional basic science trial for Influenza focused on measuring Vaccination, Trained immunity, Immunosenescence, Inflammaging
Eligibility Criteria
Inclusion Criteria:
- Age between 18-35 years old OR age ≥60 years old
- Written informed consent
Exclusion Criteria:
- Known allergy to (components of) the influenza or herpes zoster vaccine
- Immunocompromised subjects and subjects with active malignancy within the last two years
- Previous herpes zoster vaccination in the last year
- Receipt of any vaccination 4 weeks prior to the start of the study or plans to receive any other vaccination in the first 2 months after inclusion
- Use of systemic immunomodulatory drugs:steroids, anti-inflammatory biological treatments (e.g. anti-cytokine monoclonal antibodies)
- Acute or active illness within two weeks prior to the start of the study
- Pregnant, breastfeeding or planning to become pregnant during the study period
Sites / Locations
- Radboud University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Placebo Comparator
1: Young adults herpes zoster vaccination
2: Older adults herpes zoster vaccination
3: Young adults influenza vaccination
4: Older adults influenza vaccination
5: Young adults herpes zoster vaccination related placebo
6: Young adults influenza vaccination related placebo
Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
Young adults between 18 and 35 years old will receive the influenza vaccine (Fluarix Tetra).
Adults older than 60 years of age will receive the influenza vaccine (Fluarix Tetra).
Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl). 60 days later, they will receive another placebo.
Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl).